The new coronavirus currently lacks a vaccine and effective treatments. Credit: Gerd Altmann from Pixabay.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak聽on our聽timeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

has partnered with WuXi Biologics to develop and produce human monoclonal antibodies to treat Covid-19 caused by the novel coronavirus.

The partnership, which covers Vir鈥檚 antibodies, will involve clinical development, manufacturing and commercialisation.

WuXi Biologics will be responsible for cell-line development, process and formulation development and early production for clinical development.

If the antibodies obtain regulatory approvals, WuXi Biologics holds the commercialisation rights in Greater China, while Vir has the commercialisation rights in all the remaining global markets.

WuXi Biologics Chris Chen said: 鈥淏oth WuXi Biologics and Vir felt the great urgency to develop antibodies to treat global patients provided they work in the clinic.

鈥淥ur state-of-the-art technology platform and robust global-quality supply network make us uniquely qualified in expediting the development and manufacturing of these potential treatments.鈥�

痴颈谤听discovered multiple monoclonal antibodies聽that can attach to SARS-CoV-2, obtained from people who contracted and then recovered from SARS infection.

Currently, the company is exploring whether its antibodies or other antibodies identified possess effectiveness for treatment or prophylaxis against the novel coronavirus.

CEO George Scangos said: 鈥淚n the event that we are in a position to develop an antibody therapy, our agreement with WuXi Biologics enables us to accelerate advancement against this global threat.鈥�

Last month, Vir said that the company is using different platforms to determine if its previously identified mAbs against coronavirus can bind and neutralise the virus.

The company is using its antibody technology to isolate antibodies specific for SARS-CoV-2.

See all Coronavirus vaccines and drugs in the pipeline